Topic Review
Primary Biliary Cholangitis
Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune liver disease characterized by inflammation and damage of small bile ducts that frequently progress to liver cirrhosis and predominantly affects females. The key moment in the pathophysiology of the disease is loss of tolerance to PDC-E2, pyruvate subunit of the complex of dehydrogenase enzyme, located in the mitochondrial membrane. Combined genetic, epigenetic and environmental factors trigger the initial damage of the biliary epithelium in PBC, followed by the multilineage immune/inflammatory response to damaged cholangiocytes resulting in development of chronic biliary inflammatory disease.
  • 552
  • 27 Oct 2020
Topic Review
Comparison of Histone H3K4me3
Histones are alkaline proteins that package DNA into nucleosomes. H3K4me3 is highly enriched in gene promoter regions. A gain in H3K4me3 enrichment is associated with active gene transcription, open chromatin, and loss of DNA methylation. H3K4me3 has been adopted as a marker to identify transcriptionally active genes.
  • 552
  • 03 Sep 2021
Topic Review
MRNA-Enhanced Cell Therapy
mRNA has emerged as an important biomolecule in the global call for the development of therapies during the COVID-19 pandemic. Synthetic in vitro-transcribed (IVT) mRNA can be engineered to mimic naturally occurring mRNA and can be used as a tool to target “undruggable” diseases. Recent advancement in the field of RNA therapeutics have addressed the challenges inherent to this drug molecule and this approach is now being applied to several therapeutic modalities, from cancer immunotherapy to vaccine development.
  • 552
  • 03 Feb 2021
Topic Review
DAXX
The Death-domain associated protein 6 (DAXX) is an evolutionarily conserved and ubiquitously expressed protein that is implicated in many cellular processes, including transcription, cellular proliferation, cell cycle regulation, Fas-induced apoptosis, and many other events.
  • 551
  • 08 Mar 2021
Topic Review
Neutrophil Apoptosis as A Powerful Anti-Inflammatory Signal
Neutrophils are highly abundant circulating leukocytes that are amongst the first cells to be recruited to sites of infection or sterile injury. Their ability to generate and release powerful cytotoxic products ties with their role in host defence from bacterial and fungal infections. Neutrophilic inflammation is tightly regulated to limit the amount of ‘bystander injury’ caused. Neutrophils were in the past regarded as short-lived, indiscriminate killers of invading microorganisms. Neutrophils are recognised to also have important anti-inflammatory functions that are critical for the resolution of inflammation and return to homeostasis.
  • 551
  • 30 Dec 2022
Topic Review
Deubiquitinases in Regulated Cell Death
The mechanisms and physiological implications of regulated cell death (RCD) have been extensively studied. Among the regulatory mechanisms of RCD, ubiquitination and deubiquitination enable post-translational regulation of signaling by modulating substrate degradation and signal transduction. Deubiquitinases (DUBs) are involved in diverse molecular pathways of RCD. Some DUBs modulate multiple modalities of RCD by regulating various substrates and are powerful regulators of cell fate.
  • 551
  • 05 May 2021
Topic Review
Single-Cell Adhesion Force Kinetics
Cells exert, sense, and respond to the different physical forces through diverse mechanisms and translating them into biochemical signals. The adhesion of cells is crucial in various developmental functions, such as to maintain tissue morphogenesis and homeostasis and activate critical signaling pathways regulating survival, migration, gene expression, and differentiation. More importantly, any mutations of adhesion receptors can lead to developmental disorders and diseases. 
  • 551
  • 27 Apr 2021
Topic Review
Human Cell and Organoid Models
Metabolic (dysfunction) associated fatty liver disease (MAFLD) is one of the most prevalent liver diseases and has no approved therapeutics. The high failure rates witnessed in late-phase MAFLD drug trials reflect the complexity of the disease, and how the disease develops and progresses remains to be fully understood. In vitro, human disease models play a pivotal role in mechanistic studies to unravel novel disease drivers and in drug testing studies to evaluate human-specific responses.
  • 550
  • 25 Oct 2022
Topic Review
Radiotracers Available for Cancer and Disease
Various factors have been linked to abnormal metabolic reprogramming, including gene mutations, epigenetic modifications, altered protein epitopes, and their involvement in the development of disease, including cancer. The presence of multiple distinct hallmarks and the resulting cellular reprogramming process have gradually revealed that these metabolism-related molecules may be able to be used to track or prevent the progression of cancer. Consequently, translational medicines have been developed using metabolic substrates, precursors, and other products depending on their biochemical mechanism of action. It is important to note that these metabolic analogs can also be used for imaging and therapeutic purposes in addition to competing for metabolic functions. In particular, due to their isotopic labeling, these compounds may also be used to localize and visualize tumor cells after uptake.
  • 549
  • 10 Feb 2023
Topic Review
Drug Repositioning of PD-1/PD-L1 Checkpoint
Monoclonal antibodies targeting the PD-1/PD-L1 immune checkpoint have considerably improved the treatment of some cancers, but novel drugs, new combinations, and treatment modalities are needed to reinvigorate immunosurveillance in immune-refractory tumors. An option to elicit antitumor immunity against cancer consists of using approved and marketed drugs known for their capacity to modulate the expression and functioning of the PD-1/PD-L1 checkpoint. Specifically, the repositioning of the approved drugs liothyronine, azelnidipine (and related dihydropyridine calcium channel blockers), niclosamide, albendazole/flubendazole, and a few other modulators of the PD-1/PD-L1 checkpoint (repaglinide, pimozide, fenofibrate, lonazolac, propranolol) is presented. Their capacity to bind to PD-L1 or to repress its expression and function offer novel perspectives for combination with PD-1 targeted biotherapeutics. These known and affordable drugs could be useful to improve the therapy of cancer.
  • 549
  • 22 Jul 2022
  • Page
  • of
  • 161
ScholarVision Creations